Wednesday, October 21, 2015

'Dallas Buyers' Club' for Hep C treatments under investigation

'Dallas Buyers' Club' for Hep C treatments under investigation
Jane Lee

A "Dallas Buyers Club" of doctors and patients importing potentially life-saving Hepatitis C medication from countries like China is being investigated by the Therapeutic Goods Administration.

The FixHepC Buyers Club, established in September, helps patients with a doctor's prescription import and test the drugs for their personal use for cheaper rates from China and India. Visits to the group's website soared from 5000 to more than 217,000 in its first week after a Fairfax Media report.

Labor Senator Jan McLucas asked Department of Health representatives about the practice at a senate estimates hearing on Wednesday night: "What is the TGA's position on doctors establishing a so-called Dallas Buyers' Club to bypass the Pharmaceutical Benefits' Scheme and import drugs such as Harvoni and Sovaldi from China?"

Adjunct Professor John Skerritt, a deputy secretary of the Department, said that the TGA was investigating the lawfulness of the importation and the advertising of such drugs.

Continue reading...

Tuesday, October 20, 2015

Medicare covered $4.6B in hep C scripts for H1, and Gilead's the big winner

Medicare covered $4.6B in hep C scripts for H1, and Gilead's the big winner
October 20, 2015 | By Tracy Staton
Hepatitis C drugs were a big-ticket item for Medicare last year. They're on track to be even bigger this year. As ProPublica reports, Medicare Part D spent nearly $4.6 billion on hep C treatments for the first half of 2015--almost as much as paid for 2014 total. And according to script numbers, Gilead Sciences will reap the lion's share of that spending.

October 2015 Updates
Reducing the cost of new hepatitis C drugs
An index of articles pointing the reader to the current controversy over the high price of hepatitis C medications.

AASLD 2015: Late-breaking abstracts [PDF] are now available for download.

The 66th Liver Meeting of the American Association for the Study of Liver Diseases will take place in San Francisco, California between 13th and 17th November 2015.

AASLD expects more than 9500 hepatologists and hepatology health professionals from all over the world to exchange the latest liver disease research, discuss treatment outcomes and networking with colleagues.

The Liver Meeting® 2015 abstract supplement, in full text, is available as a PDF, and online in a special issue of Hepatology.

Researchers find possible link between marijuana, HCV

Researchers find possible link between marijuana, HCV

HONOLULU — Any use of marijuana was found to be associated with a positive hepatitis C antibody serum test, according to a poster presentation at ACG 2015.

Akeem O. Adebogun, MD, MPH, of Howard University Hospital, Washington, DC, and colleagues extracted and analyzed data from the National Health and Nutrition Examination Survey of 7,821 patients with HCV between 2011 and 2012. The goal was to determine any link or impact marijuana and further drug use had on a hepatitis C antibody test.

Continue Reading @ Healio

See more from Highlights from ACG 2015

Merck to Present New Data on HCV Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015

Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations

New Data Will Also be Presented from Phase 2a C-CREST Trials of Merck’s Investigational Triple-Combination Chronic Hepatitis C Therapies

KENILWORTH, N.J., Oct 20, 2015 (BUSINESS WIRE) -- Merck MRK, -1.56% known as MSD outside the United States and Canada, today announced that new data from clinical trials of its investigational treatment portfolio for chronic hepatitis C virus (HCV) are scheduled to be presented at The Liver Meeting [®] 2015 (the 66 [th] annual scientific congress of the American Association for the Study of Liver Diseases) in San Francisco, from Nov. 13-17, 2015. Merck’s late-stage investigational portfolio includes elbasvir/grazoprevir [1] , MK-3682 [2] and MK-8408 [3] .

A range of data will be presented from more than 20 accepted abstracts. Among these are two late-breaking abstracts from the C-CREST and C-SWIFT clinical trial programs.

“Recent innovations in the treatment of chronic hepatitis C are enabling health systems and physicians to address the burden of this disease. Continued innovation is essential, particularly for patients for whom current therapies may not be suitable,” said Dr. Eliav Barr, vice president, infectious diseases, Merck Research Laboratories. “Merck is committed to evaluating our chronic hepatitis C investigational medicines in a broad range of patients and treatment durations to help address the global unmet needs that still exist.”

Elbasvir/grazoprevir is currently under Priority Review with the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) action date of Jan. 28, 2016.

Key Presentations of Interest
Oral Presentations for Elbasvir/Grazoprevir
Sunday, Nov. 15:
C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (Abstract #40, 3:45 – 4:00 p.m. PST)
An Integrated Analysis of 402 Compensated Cirrhotic Patients With HCV Genotype (GT) 1, 4 or 6 Infection Treated With Grazoprevir/Elbasvir (Abstract #42, 4:15 – 4:30 p.m. PST)

Tuesday, Nov. 17:
High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6-Infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGECoinfection Study (Abstract #210, 9:15 – 9:30 a.m. PST)
High Efficacy of Grazoprevir and Elbasvir With or Without Ribavirin in 103 Treatment-Naive and Experienced Patients With HCV Genotype 4 Infection: A Pooled Analysis (Abstract #251, 12:15 – 12:30 p.m. PST)

Late-Breaking Presentations
Monday, Nov. 16:
Poster: Prevalence and Impact of Baseline NSA Resistance Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) against GT1a Infection (Abstract #LB-22)
Poster: Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2) (Abstract #LB-15)
Poster:C-SWIFT Retreatment (Part B): 12 weeks of Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated GT1-infected Subjects who Failed Short-Duration All-Oral Therapy (Abstract #LB-12)

Select Poster Presentations for Elbasvir/Grazoprevir
Saturday, Nov. 14:
Projected Long-Term Impact of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease (Abstract #727)
C-EDGE Co-Infection: Impact of 12-Week Oral Regimen of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) on Patient-Reported Outcomes (PROs) in Treatment-Naïve Patients with HCV/HIV Co-infection (Abstract #729)
C-EDGE TN: Impact of 12-Week Oral Regimen of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) on Patient-Reported Outcomes (PROs) in Treatment-Naïve Patients with Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection (Abstract #717)
High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive, Noncirrhotic HCV GT1b–Infected Patients: An Integrated Analysis (Abstract #701)
Predictors of Response to Grazoprevir/Elbasvir Among HCV Genotype 1 (GT1)–Infected Patients: Integrated Analysis of Phase 2-3 Trials (Abstract #700)
Safety and Tolerability of Grazoprevir/Elbasvir in Patients With Chronic Hepatitis C (HCV) Infection: Integrated Analysis of Phase 2-3 Trials (Abstract #712)
The Combination of Grazoprevir and Elbasvir ± RBV is Highly Effective for the Treatment of GT1a-Infected Patients (Abstract #703)
Efficacy, Safety And Pharmacokinetics Of Grazoprevir (MK-5172) And Elbasvir (MK-8742) In Hepatitis C Genotype 1 Infected Non-Cirrhotic Japanese Patients (Phase 2 Portion In Phase 2/3 Combined Study) (Abstract #707)

For more information, including a complete list of abstract titles, please visit:
About Elbasvir/Grazoprevir

Elbasvir/grazoprevir is Merck’s investigational, once-daily, fixed-dose combination therapy containing elbasvir (HCV NS5A replication complex inhibitor) and grazoprevir (HCV NS3/4A protease inhibitor). Merck’s broad clinical trials program includes evaluations of elbasvir/grazoprevir with or without ribavirin for multiple HCV genotypes, together with patients with difficult-to-treat conditions such as cirrhosis, advanced chronic kidney disease, HIV/HCV co-infection, inherited blood disorders and those on opiate substitution therapy. In July 2015, the U.S. Food and Drug Administration (FDA) granted Priority Review for the New Drug Application for elbasvir/grazoprevir, with a Prescription Drug User Fee Act (PDUFA) action date of Jan. 28, 2016.

In April 2015, the FDA granted Breakthrough Therapy designation for elbasvir/grazoprevir for the treatment of patients with chronic HCV GT1 infection with end stage renal disease on hemodialysis, and Breakthrough Therapy designation for elbasvir/grazoprevir for the treatment of patients with chronic HCV GT4 infection. Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Merck’s Commitment to HCV
For nearly 30 years, Merck has been at the forefront of the response to the HCV epidemic. Merck employees are dedicated to applying their scientific expertise, resources and global reach to deliver innovative healthcare solutions that support people living with HCV worldwide.

About Merck
Today’s Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook andYouTube.

Forward-Looking Statement of Merck & Co. Inc., Kenilworth, NJ, USA
This news release of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

[1] Elbasvir is an HCV NS5A replication complex inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor
[2] MK-3682 is an oral prodrug HCV nucleotide analogue NS5B polymerase inhibitor
[3] MK-8408 is an HCV NS5A replication complex inhibitor

Monday, October 19, 2015

Hep C: The Pan-Virals Are on the Way

Hep C: The Pan-Virals Are on the Way
Conference Coverage > ACG 2015
Oct 19, 2015 | Gale Scott

With the ever-growing arsenal of antivirals to cure hepatitis C infection, physicians still have to be mindful of which of the six hepatitis virus genotypes their patient has. No drug work for all genotypes.

That could change next year. The pan-virals are coming.

Speaking at a symposium on treatments for hepatitis C at the American College of Gastroenterology Annual Scientific Meeting in Honolulu Oct 18, Mitchell Shiffman, MD, director of the Liver Institute of Virginia, Bon Secours Health System, Richmond, VA, said the newest drug candidates are expected to work on all genotypes of the virus.

Decentralized HCV Treatment is Effective!

Decentralized HCV Treatment is Effective!
Posted on October 18, 2015
The American Journal Of Medicine

Given the safety, tolerability, simplicity, and efficacy of hepatitis C direct-acting antiviral (DAA) regimens, decentralizing treatment from gastroenterologists and hepatologists to other specialists, community-based primary care physicians, or appropriately supervised mid-level providers (ie, task-shifting) may be an effective strategy to increase treatment rates, cure rates, and really start addressing to the HCV epidemic. The SVR-12 rates achieved by a US rural outreach program based on the task-shifting model—88 % overall, 86 % in genotype 1 patients, 94 % in genotype 2 patients, and 83 % in genotype 3 patients—are comparable to those achieved in phase II and III clinical trials utilizing these regimens. By utilizing task-shifting, wherein a local mid-level provider monitored patients on DAA treatment with indirect supervision of a specialist, high rates of treatment adherence and success in medically underserved areas was achieved.

Sunday, October 18, 2015

2015-2016 Influenza Season: Importance of getting vaccinated if you have HCV or underlying liver disease

2015-2016 Influenza Season
Its that time of year folks, time to get your flu shot. Not only is it the first and most important step you can take in protecting yourself, it also protects everyone around you. 

If you need a reason for getting that flu shot, having chronic hepatitis C is reason enough. The CDC recommends everyone 6 months of age and older should get vaccinate, and since 2007 the Advisory Committee on Immunization Practices in the USA has recommended annual influenza vaccination for patients with chronic liver disease. As people with chronic liver disease are at a higher risk for flu-related complications, especially people with cirrhosis, and liver transplant recipients.

The Flu And Hepatitis C
October 18
Published this weekend over at; HCV Advocate News And Pipeline Blog, is an overview article featuring symptoms of influenza, risk, prevention, and advice for anyone who may come down with the flu this season, written by Alan Franciscus.

The Five: The Flu —Alan Franciscus, Editor-in-Chief
This year’s strains of influenza are particularly virulent, and unfortunately the vaccine developed this year does not provide protection against all of the strains. The flu is a nasty virus that causes 36,000 deaths and 200,000 hospitalizations each year in the United States. The largest and deadliest flu outbreak was the Spanish flu pandemic of 1918-1919 that caused 20 to 40 million deaths. Now we are lucky to have a healthcare system that prevents most deaths, and vaccines that provide protection against most strains of the flu.

In addition check out two great articles offering general information about the importance of getting vaccinated if you have HCV or underlying liver disease. The first article written by Jennifer J. Brown, PhD, was recently published over at Everyday Health; The Flu and Hepatitis C: Higher Risk of Complications, the second article was written last month by our very own advocate Lucinda K. Porter, RN., Hepatitis C or No Hepatitis C, Get a Flu Shot

Of Interest
Dear Flu Vaccine: Please Improve!
Paul E. Sax, MD
From: HIV and ID Observations
An ongoing dialogue on HIV/AIDS, infectious diseases, all matters medical, and some not so medical. a patient of mine refused his flu shot this past week — “it gives me the flu” he (wrongly) said — I became motivated to reach out and let you know exactly what you should start working on....
Continue reading...

Any flu shot is a good flu shot
Keith Roach, To Your Health

Dear Dr. Roach: For the 2015-2016 flu season, we find a trivalent vaccine (three influenza virus), quadrivalent vaccine (four influenza virus) and high-dose trivalent recommended for seniors 65 and older. As a member of the senior group, I would like your opinion on the best choice. Why do they still supply the trivalent when the quad protects against four flu viruses? The high-dose trivalent is only for seniors, but the quad seems to be a better choice. This is confusing; please help us understand.

Dear J.H.: Let me preface my answer by saying that any influenza vaccine will provide some protection against flu.

There actually are six different types of FDA-approved flu vaccines available for the 2015-2016 season. In addition to the three you mention (standard- and high-dose trivalent and quadrivalent), there also are two trivalent vaccines made without eggs (particularly useful for those with an egg allergy); an intradermal vaccine that uses a tiny needle (90 percent smaller than regular needles) for people who really don’t like shots; and, unlike all other flu vaccines (which are inactivated virus), a live attenuated vaccine given via a nasal spray, which may be better in children, and is approved only for ages 2-49.

If you do have a choice, I would recommend the high-dose trivalent for those over 65, and the quadrivalent for those under 65, unless you fall into one of the special situations above (fear of shots, egg allergy).

Forget Last Year's Hiccups, Go Get Your Flu Shot
October 19, 2015 5:14 AM ET
Patti Neighmond
Last year, public health officials were taken by surprise when new strains of the flu virus appeared. Not so this year and they advise everyone six months or older to get vaccinated against the flu.

Vaccine Options
This year there are several vaccine options which protect against the three or four flu viruses experts anticipate may circulate this season. To learn more about this years flu vaccine start by reading the CDC's Questions & Answers or watch last months news conference with public health experts discussing the coming flu season, as well as important CDC data from last years season, both available below.

Questions & Answers Seasonal Flu Shot
Traditional flu vaccines made to protect against three different flu viruses (called “trivalent” vaccines) are available. In addition, flu vaccines made to protect against four different flu viruses (called “quadrivalent” vaccines) also are available.

Trivalent flu vaccine protects against two influenza A viruses (an H1N1 and an H3N2) and an influenza B virus. The following trivalent flu vaccines are available:

Standard-dose trivalent shots that are manufactured using virus grown in eggs. There are several different flu shots of this type available, and they are approved for people of different ages. Some are approved for use in people as young as 6 months of age. Most flu shots are given with a needle. One standard dose trivalent shot also can be given with a jet injector, for persons aged 18 through 64 years.

A high-dose trivalent shot, approved for people 65 and older.

A trivalent shot containing virus grown in cell culture, which is approved for people 18 and older.

A recombinant trivalent shot that is egg-free, approved for people 18 years and older.

The quadrivalent flu vaccine protects against two influenza A viruses and two influenza B viruses. The following quadrivalent flu vaccines are available:

A quadrivalent flu shot that is manufactured using virus grown in eggs. There are several different flu shots of this type available, and they are approved for people of different ages. Some are approved for use in people as young as 6 months of age.

An intradermal quadrivalent shot, which is injected into the skin instead of the muscle and uses a much smaller needle than the regular flu shot. It is approved for people 18 through 64 years of age.

A quadrivalent nasal spray vaccine, approved for people 2 through 49 years of age.

Read more; Questions & Answers Seasonal Flu Shot
More information about influenza vaccines is also available at Preventing Seasonal Flu With Vaccination.


The National Foundation for Infectious Diseases 

2015 NFID Influenza/Pneumococcal News Conference
September 17, 2015

Flu seasons can vary in severity, but flu takes a toll on public health each year in the United States, causing illness in millions, hospitalizing hundreds of thousands and killing thousands or tens of thousands of individuals. Last season, recorded hospitalization rates for people age 65 years and older were the highest ever seen since surveillance began in 2005, and 145 children were reported to have died from flu.

Tom Frieden, M.D., M.P.H., director of the Centers for Disease Control and Prevention (CDC), joined by other leading medical and public health experts, discuss preparing the public for the coming flu season at a news conference presented by the National Foundation for Infectious Diseases (NFID).

Press Release
Download Each Transcript Of The Meeting
News Conference Transcript
News Conference Transcript

AARP  - Reporting On The News Conference 
Posted on 09/17/2015

CDC: Flu Shot Should Be Better This Season
by Candy Sagon 

With flu season about to start, health officials reassured Americans that the new, updated flu vaccine now available should do a better job than last year’s.

The 2014-15 flu season was particularly nasty, thanks to a major flu strain that changed after the vaccine had already been manufactured. As a result, last year’s vaccine was only 13 percent effective against the virulent H3N2 strain, causing the highest hospitalization rate among older adults that the Centers for Disease Control and Prevention (CDC) had ever recorded, said director Thomas Frieden.

This year’s vaccine should be better, Frieden said at a Thursday news conference, where he rolled up his sleeve and got his own flu shot. An analysis of the flu strains in about 200 early cases this year finds that most matched the strains in this season’s vaccine and all were susceptible to antiviral medications. “So far what we’ve seen is encouraging,” he said.

Still, flu is unpredictable. “Influenza viruses are always mutating. It’s their natural evolution. You just hope the mutations remain small enough” that the vaccine is still effective against them, said influenza researcher Pedro Piedra, M.D., with the Baylor College of Medicine in Houston.

Even at its best, the flu vaccine is only 50 to 60 percent effective, but it’s biggest benefit is protecting against the disease’s most severe consequences, such as hospitalization and death, Piedra told AARP. That’s why it’s so important for older adults — especially those 65 or older — to get a vaccine, since they are the ones the most hard hit, Piedra said.

For those of you who pooh-pooh getting a flu shot — and according to the CDC, that’s more than 50 percent of Americans — then don’t do it for yourself, do it to protect those around you, such as children and the elderly, Piedra said. “Getting a vaccine helps create a bigger zone of protection around the most vulnerable, making it harder for the viruses to take hold.”

The CDC estimates that only 47 percent of the U.S. population was vaccinated last season. And while 67 percent of those 65 or older got their flu shot, that still leaves millions at risk.

As Kaiser Health News reported, the most recent CDC data shows that 1 in 3 seniors each year skips the flu vaccine, and vaccination rates for those who are 65-plus haven’t increased much — hovering around 65 percent for more than 15 years. The federal government’s goal is 90 percent by 2020.

To combat this year’s flu, more than 170 million doses of flu vaccine are being produced, and 40 million have already been distributed. Among the options are traditional shots, including one with a much smaller needle; a nasal spray; a high-dose version for seniors; an egg-free vaccine — even a needle-free jet injector for the squeamish.

“Vaccination is easier and more convenient than ever,” the CDC’s Frieden said. “It’s the best way to protect yourself, your family and your community against flu.”


2015 The Summit Buzz
October 12, 2015 Updates  

Patients with Influenza-Associated Pneumonia Less Likely to Have Received Flu Vaccine
Among children and adults hospitalized with community-acquired pneumonia, those with influenza-associated pneumonia, compared with those with pneumonia not associated with influenza, had lower odds of having received an influenza vaccination, according to a study published online by JAMA. A press release on the study also is available.

CDC Publishes Guidance on What to Expect for the 2015–2016 Influenza Season
CDC has developed a new web page titled What You Should Know for the 2015-2016 Influenza Season. This web page features sections on what to expect for the upcoming flu season, information on what viruses may circulate, and other general information for the upcoming flu season.

Influenza Vaccine Doses Distributed
As of September 25, 2015, approximately 92.3 million doses of influenza vaccine have been distributed. This is out of an approximately 171–173 million doses that are estimated to be made by manufacturers this season. Updated vaccine distribution data may be found on the CDC website.

CDC/Influenza Division Weekly Influenza Surveillance Report and CDC Key Points
2015-2016 Influenza Season Week 40 ending October 10, 2015

The CDC weekly influenza surveillance report for week 40, 2015 (ending October 10, 2015) and region specific data are now available.

Summit Call Recap – October 1, 2015

2015 NFID Annual Influenza/Pneumococcal News Conference – Marla Dalton (NFID)

View all updates, here

About the Summit
What is the National Adult and Influenza Immunization Summit?

The National Adult and Influenza Immunization Summit (NAIIS) is dedicated to addressing and resolving adult and influenza immunization issues. The NAIIS consists of over 700 partners, representing more than 130 public and private organizations. Summit participants include a wide range of professionals from the healthcare industry, public health and private medical sectors, vaccine manufacturers and distributors, consumers, and others interested in stopping the transmission of vaccine-preventable diseases.

Just For Fun 

The Flu Fighters Parody - Shake It Off

Beth Israel Deaconess Medical Center Shakes It Off to keep the flu away!

Good Health Habits for Preventing Seasonal Flu
In addition to getting vaccinated, you and your loved ones can take everyday preventive actions like staying away from sick people and washing your hands to reduce the spread of germs. If you are sick with flu, stay home from work or school to prevent spreading influenza to others.

May we all remain healthy this flu season.